Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15651
R64622
Blotière (Indications other than epilepsy), 2019 Hypospadias 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 0.90 [0.10;3.30] 2/-   3,371/- 3,373 -
ref
S15601
R64298
Tinker (Mixed indications), 2019 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 0.80 [0.20;2.70] 5/-   2,535/- 2,540 -
ref
S17865
R75477
Eros (Indications NOS), 2002 Hypospadias during pregnancy (anytime or not specified) excluded case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched 1.00 [0.10;15.00]
excluded (exposition period)
1/-   -/- - -
ref
Total 2 studies 0.83 [0.29;2.37] 5,913 0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Indications other than epilepsy), 2019Blotière, 2019 1 0.90[0.10; 3.30]3,373-36%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker (Mixed indications), 2019Tinker, 2019 2 0.80[0.20; 2.70]2,540-64%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 0% 0.83[0.29; 2.37]5,913-0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.90[0.16; 5.17]3,373- -NABlotière (Indications other than epilepsy), 2019 1 case control studiescase control studies 0.80[0.22; 2.94]2,540- -NATinker (Mixed indications), 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.83[0.29; 2.37]5,913-0%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 Tags Adjustment   - No  - No 0.90[0.16; 5.17]3,373- -NABlotière (Indications other than epilepsy), 2019 1   - Yes  - Yes 0.80[0.22; 2.94]2,540- -NATinker (Mixed indications), 2019 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 0.90[0.16; 5.17]3,373- -NABlotière (Indications other than epilepsy), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 0.80[0.22; 2.94]2,540- -NATinker (Mixed indications), 2019 1 All studiesAll studies 0.83[0.29; 2.37]5,913-0%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.83[0.29; 2.37]5,913-0%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (Clonazepam) (All indication ...Veroniki a (NMA) (Clonazepam) (All indications) (Hypospadias) 6.17[1.17; 24.80]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT-9 metaPregmetaPreg 0.83[0.29; 2.37]0%-----Blotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.510.01.0